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Peroxisome proliferator-activated receptors (PPARs): Novel inducers of hepatic peroxisomal proliferation. In rodents,
therapeutic targets in renal disease. Peroxisome proliferator- chronic exposure to peroxisome proliferators results in
activated receptors (PPARs) are members of the nuclear hor- nongenotoxic liver tumors [1] and alters gene expressionmone receptor superfamily of ligand-dependent transcription
involved in lipid -oxidation, cell differentiation and in-factors. PPARs play an important role in the general transcrip-
flammation [2]. These effects are now known to be medi-tional control of numerous cellular processes, including lipid
metabolism, glucose homeostasis, cell cycle progression, cell ated through binding of peroxisome proliferators to a
differentiation, inflammation and extracellular matrix remodel- specific subset of nuclear receptor and transcription fac-
ing. Three PPAR isoforms, designated PPAR, PPAR and tor superfamily, designated peroxisome proliferator-PPAR, have been cloned and are differentially expressed in
activated receptors (PPARs). Since the identification ofseveral tissues including the kidney. PPAR primary regulates
the first PPAR receptor in mouse [3], three isoforms—lipid metabolism and modulates inflammation. PPAR is the
molecular target of the hypolipidemic fibrates including be- designated PPAR, PPAR/ and PPAR—have been
zafibrate and clofibrate. PPAR participates in embryonic de- cloned and characterized by their distinct expression pat-
velopment, implantation and bone formation. PPAR is a key terns, different ligand binding specificity and metabolic
factor in adipogenesis and also plays an important role in insu-
functions. In the past decade, tremendous progress haslin sensitivity, cell cycle regulation and cell differentiation.
been made towards understanding the role of PPARsAntidiabetic thiazolidinediones (TZDs) such as troglitazone
and rosiglitazone are specific ligands of PPAR, and this inter- in whole body physiology and in many human diseases
action is responsible for the insulin-sensitizing and hypoglyce- including diabetes, obesity, atherosclerosis, hypertension
mic effect of these drugs. The kidney has been shown to differ- and cancer. PPAR plays an important role in lipid me-entially express all PPAR isoforms. PPAR is predominantly
tabolism and its activation by fibrates mediates theirexpressed in proximal tubules and medullary thick ascending
potent hypolipidemic effects [4]. Recently, PPAR/ haslimbs, while PPAR is expressed in medullary collecting ducts,
pelvic urothelium and glomerular mesangial cells. PPAR is been suggested as having an important role in cell sur-
ubiquitously expressed at low levels in all segments of nephron. vival and colon tumorigenesis. It has been suggested as
Accumulating data has begun to emerge suggesting physiologi- a molecular target mediating the beneficial effect of non-cal and pathophysiological roles of PPARs in several tissues
steroidal anti-inflammatory drugs (NSAIDs) on colorectalincluding the kidney. The availability of PPAR-selective ago-
cancer [5]. Finally, activation of PPAR by syntheticnists and antagonists may provide a new approach to modulate
the renal response to diseases including glomerulonephritis, thiazolidinedione (TZD) ligands has been successfully
glomerulosclerosis and diabetic nephropathy. used for treatment of patients with type II diabetes [6].
This review examines the current knowledge relating to
PPARs’ action, ligand binding and tissue distribution.
Peroxisome proliferators comprise a group of structur- Recent developments regarding the role of PPARs in
ally diverse compounds including industrial chemicals and diabetes, insulin resistance, atherosclerosis, inflamma-
pharmaceutical agents that were originally identified as tory disease, hypertension, and cancer, with particular
relevance to the kidney will also be discussed.
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Fig. 1. (A) Structural and functional domains
of the human peroxisome proliferator-acti-
vated receptors (PPARs). Domains are: A/B,
N-terminal A/B domain containing a ligand-
independent activation function (AF-1); C,
DNA-binding domain (DBD); D, hinge re-
gion; and E/F, C-terminal ligand-binding do-
main (LBD) containing the ligand-dependent
activation function (AF-2). Numbers inside
the boxes represent the percentage (%) iden-
tity between the human PPAR isofoms. (B)
The genomic organization of the human
PPAR gene. Alternative promoter usage and
splicing of the three 5 exons A1, A2, and B
results in three different transcripts and two
PPAR protein products (PPAR1 and
PPAR2). Note that transcription from the
promoter 1 and 3 results in same protein
of 477 amino acids (PPAR1protein) and tran-
script using the promoter 2 encoded a protein
of 505 amino acids (PPAR2 protein), which
has additional 28 amino acids at the N-termi-
nus compared with PPAR1 protein.
screening of cDNA library with a probe encoding the All three PPAR isoforms share similar structural and
functional organization with other nuclear receptorshighly conserved C domain of nuclear hormone recep-
tors [3]. This receptor is now designated PPAR. Shortly (Fig. 1). Four major domains have been identified: A/B,
C, D and E/F domain [reviewed in 2, 11]. The N-terminalthereafter, two additional isoforms of PPAR were identi-
fied: PPAR/ and PPAR [7]. To date, no mRNA splice A/B domain differs in both length and predicted amino
acid sequence and contains a ligand-independent trans-variant for PPAR and PPAR/ has been identified.
In contrast, multiple splicing forms of PPAR mRNA activation domain, termed activation function 1 (AF1).
This domain plays an important role in regulating PPARhave been reported in many species including mouse
and human [8–10]. In humans three PPAR transcripts activity through both phosphorylation and interdomain
communication [12, 13]. The C domain is comprised ofhave been reported [9]. These three isotypes of PPAR
are derived from a single gene as a result of differential about 70 amino acids and encodes the DNA binding
domain (DBD). This domain is responsible for the bind-splicing and alternate promoter usage (Fig. 1). Each
PPAR transcript shares the six 3 coding exons, dif- ing of PPAR receptor to peroxisome proliferator re-
sponse element (PPRE) in the promoter region of targetfering only in the 5 exons. The 5 untranslated region
of PPAR1 contains exons A1 and A2, while PPAR3 genes. The D hinge region is a docking domain for cofac-
tors. The E/F C-terminal region contains two importantonly contains exon A2. Since none of the 5 exons distin-
guishing PPAR1 and PPAR3 possess a translation domains. One is the ligand-binding domain (LBD), or
E domain, responsible for ligand specificity and activa-initiation site, PPAR1 and PPAR3 mRNAs give rise
to identical protein products: PPAR1. In contrast, tion of PPAR binding to the peroxisomal proliferator
response element (PPRE) with resultant modulation ofPPAR2 has a 2-specific coding exon located between
exon A2 and exon 1, yielding 30 additional N-terminal gene expression. This region also has been found to play
an important role in dimerization and nuclear localiza-amino acids in the PPAR2 protein [6, 11]. Due to differ-
ent promoter usage, each PPAR isoform has a distinct tion. The other is the ligand-dependent activation do-
main AF-2, or F domain. AF-2 domain located in theexpression pattern [9, 10].
Guan and Breyer: PPARs in renal disease16
Fig. 2. Model for gene activation and repression by PPAR.
C-terminal -helix 12 is critical for both ligand-binding PPAR activators, including hypolipidemic compounds
WY-14,643 and clofibrate. Importantly, these compoundsand recruitment of PPAR cofactors.
exhibit a good correlation between ability to activate
PPAR ligands PPAR and the potency to induce hepatocarcinoma in
rodents, suggesting that PPAR is the major molecularSimilar to other members of the nuclear receptor fam-
target of hepatocarcinogenic peroxisome proliferators inily, PPARs are ligand-activated transcriptional factors,
the liver [15].that is, modulation of target gene transcription depends
PPAR is highly expressed in adipose tissue where iton the binding of the ligands to the receptor. PPARs
plays a critical role in adipocyte differentiation. Antidia-form heterodimers with the 9-cis retinoic acid receptor,
betic TZD including troglitazone and rosiglitazone pro-RXR. Activation of PPAR:RXR by PPAR ligands
mote adipocyte differentiation through activation ofand/or RXR ligands results in a conformational change
PPAR [16–20]. In vitro, these TZDs have been shownof these receptors, allowing the heterodimers to bind
to bind PPARwith a kD of 30 to 10,000 nmol/L [21, 22].PPREs in target genes and modulate the gene transcrip-
A synthetic compound, L-165041, selectively activatestion (Fig. 2). The divergent amino acid sequence in the
PPAR/ at high affinity (kD  6 nmol/L) with veryLBD of the three PPAR isoforms provides the molecular
poor affinity for PPAR and no affinity to PPAR [23].basis for ligand specificity. Since PPARs have a large
ligand-binding pocket (1300 A˚) [14], these receptors are A search for naturally occurring ligands reveals that PPAR
receptors are also activated by numerous fatty acid atcapable of binding several structurally diverse compounds,
including industrial chemicals such as herbicides and plas- physiologic concentrations [24]. PPAR is activated by
a variety of long-chain polyunsaturated fatty acids in-ticizers as well as pharmaceutical compounds including
hypolipidemic fibrates (such as clofibrate) and antidia- cluding linoleic acid, branched, conjugated and oxidized
fatty acids such as phytanic acid, conjugated linolenicbetic thiazolidinediones (TZDs; for example, troglita-
zone and rosiglitazone). When assessed by transactiva- acid and eicosanoids such as 8S-HETE and leukotriene
B4 [25–28]. The endogenous prostaglandin D2 (PGD2)tion assays, a variety of exogenous compounds have been
shown to selectively activate PPAR isoforms (Table 1). metabolite, 15-deoxy-12,14 prostaglandin J2 (15dPGJ2)
is the most potent natural ligand of PPAR and mightAmong them, several agents have been identified as
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Table 1. Peroxisome proliferator-activated isoform [9, 33, 34]. Recently, low but significant levels
receptor (PPAR) ligands
of PPAR expression has also been detected in vascular
PPAR smooth muscle cells, endothelial cells, hepatic Stellate
Ligands  /  Reference cells, bone marrow stromal cells, monocytes/macro-
phages, and malignant epithelial cells including breast,Exogenous compounds
WY-14,643    [86, 227] colon, prostate and bladder cancer cells [36–46], sug-
Clofibrate  	 /	 [177, 230] gesting that PPAR may participate in many physiologi-
ETYA  	 /	 [228]
cal and pathophysiological events in these tissues as well.Troglitazone 	 	  [177, 230]
Rosiglitazone (BRL49653) 	 	  [177, 230] The expression of PPAR in liver is decreased by
Pioglitazone 	 	  [177, 230] insulin and increased by glucocorticoids, respectively
GW2433 	  	 [231]
[47, 48]. PPAR expression cycles in parallel with theIL-165041 	   [86, 227]
Indomethacin  	  [229] circadian rhythm of circulating glucocorticoids [49]. In
Ibuprofen  	  [229] hepatic cells and pancreatic islets, expression of PPAR
Endogenous activators
is down-regulated with treatment of growth hormonePalmitic acid (16:0)   	 [31]
Linoleic acid (18:2, n-6)    [31] [50], but up-regulated by fibrates or free fatty acid (FFA)
Arachidonic acid (20:4, n-3)    [31] [51, 52]. In humans, alternative splicing of mRNA may
PGA1    [228] play a role in regulating PPAR expression. Human liverPGD2    [228]
PGJ2  /	  [228] has a splice variant of PPAR transcript lacking exon 6.
15-Deoxy-12,14-prostaglandin J2  /	  [86] The resulting reading frame shift results in a premature
8(S)-HETE  	 	 [86, 228]
stop codon shortly after the DNA binding domain, re-LTB4 /	 ND ND [86, 200]
9-HODE ND ND  [29] sulting in a truncated PPAR protein [53]. This process
13-HODE ND ND  [29] might diminish the hepatic expression of PPAR. In
Abbreviations are in the Appendix. Symbols are: , activator; 	, not an addition, a mutation at codon 162 (L162 V) of PPAR
activator; /	, possible activator; ND is not determined.
has been shown to be associated with hyperapobetalipo-
proteinemia in humans [54].
Regulation of PPAR has been extensively investi-
gated. Insulin and corticosteroids synergistically induceplay a role in adipogenesis in vivo [21]. Interestingly,
two pathophysiological oxidized metabolites of linoleic PPAR expression, while tumor necrosis factor- (TNF-)
suppresses the PPAR level in adipocytes [55, 56]. Inacid, 9-hydroxy and 13-hydroxy octadecadienoic acids
(9-HODE and 13-HODE) present in oxidized low-den- rodents, in vivo studies revealed that PPAR expression
in adipose tissue is significantly up-regulated by high-sity lipoprotein have also been suggested as PPAR li-
gands and could play a role in atherogenesis [29, 30]. fat feeding and down-regulated by fasting [57–59]. In
humans, increased expression of the PPAR receptor hasLinoleic acid, arachidonic acid, eicosapentenoic acid
(EPA) and PGA1 have been shown to bind PPAR/ been observed in adipose tissue of obese humans [55]
and skeletal muscle of patients with obesity or type IIreceptor in the 
mol/L range [31, 32].
diabetes [55, 60, 61]. Genetic polymorphisms and muta-
tions have been also found to play a role in PPAR
PPAR ISOFORMS: TISSUE DISTRIBUTION,
function in humans [61–63]. Pro12Ala substitution of
INTRARENAL LOCALIZATION
PPAR2 is associated with decreased receptor activity,
AND FUNCTION
low body mass index (BMI), and increased insulin sensi-
Tissue distribution and regulation of PPAR isoforms tivity in nonobese subjects [62, 64]. In contrast, Pro115Gln
mutation destroys the mitogen-activated protein (MAP)Expression of the three PPAR isoforms has been ex-
amined in many species including Xenopus, rat, mouse, kinase target site in Ser112, resulting in increased activity
of PPAR and severe obesity [63]. Thus far, very littlerabbit and human. In humans, PPAR is predominantly
expressed in tissues exhibiting high catabolic rates of is known about the regulation of PPAR/ receptor.
However a recent report suggests its expression may befatty acids (adipose tissue, liver, heart, muscle, and renal
cortex) and it is also detected in lung, placenta, intestine, repressed by the adenomatous polyposis coli (APC) gene
through -catenin/Tcf-4 transcription factor [65]. Thesepancreas and skeletal muscle. PPAR/ is the most widely
expressed isotype and low levels are found in almost all data suggest a role for PPAR/ in the pathogenesis of
colon cancer.tissues examined. In general, PPAR is highly expressed
in adipose tissue and at lower levels in renal medulla,
Intrarenal localization of PPARsurinary bladder, skeletal muscle, liver, and heart [33–35].
Although all three PPAR splice variants are expressed Renal expression of PPARs have been investigated in
many species including mouse, rat, rabbit and humansin adipose tissues at high levels, PPAR2 and 3 appear
to be more restrictively expressed in fat than the 1 [34, 35, 66–68]. Northern hybridization and RNase pro-
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tection assay show that all three PPAR isoforms are ex- (ACS) [78] and apolipoproteins (apo) are also PPAR
target genes [79, 80]. In liver, PPAR is a pivotal factorpressed in the kidney. In situ hybridization analysis and
reverse transcription-polymerase chain reaction (RT- involved in every aspect of fatty acid oxidation. Triglyc-
erides in chylomicrons are extracellularly hydrolyzedPCR) provide concordant results for nephron expression
[35, 67, 69]. PPAR is predominantly expressed in proxi- into glycerol and fatty acids by the lipoprotein lipase
(LPL), another well-characterized PPAR target genemal tubules and medullary thick ascending limbs, while
PPAR is selectively expressed in medullary collecting [76, 81, 82]. The resultant nonesterified fatty acids are
then subsequently taken up by hepatocytes through theducts and pelvic urothelium. PPAR/, like in other tis-
sues, is equally expressed in renal cortex and medulla PPAR target gene, fatty acid transport protein (FATP)
[83]. Once imported into hepatocytes, fatty acids areand is expressed ubiquitously in all segments of nephron
tested. Recently, functional expression of PPAR has activated into acyl CoA thioesters by ACS. Acyl CoA
may then either be esterified or, alternatively, enter thealso been reported in freshly isolated glomeruli and cul-
tured mesangial cells in both rabbit and rat (abstract; pathway of -oxidation. Metabolizing long-chain fatty
acyl CoA (C20) via -oxidization takes place in peroxi-Guan et al, J Am Soc Nephrol 11:A3381, 2000) [70, 71].
Renal expression of PPAR isoforms is also developmen- somes. All three enzymes involved in this process have
been shown to be directly regulated by PPAR via bind-tally regulated. All three PPAR isoforms are expressed
in early embryonic kidneys. PPAR and PPAR expres- ing to the PPRE sites in the promoter region of these
genes. These genes include acyl CoA oxidase (ACO),sion is enhanced with development and remains at high
level 2 weeks after birth, while PPAR/ expression a rate-limiting enzyme, enoyl CoA hydratase/dehydroge-
nase multifunctional enzyme (HD), and keto-acyl CoApeaks in late gestation and declines after birth [69, 72].
thiolase [7, 84–86]. Long- (C14 to C20) and medium-
chain (C8 to C12) fatty acids can be oxidized either in
PHYSIOLOGICAL ROLES OF PPAR ISOFORMS
peroxisome or mitochondria. Mitochondrial -oxidation
Distinct expression patterns and differential ligand- is approximately twice as efficient as peroxisomal -oxi-
binding profiles indicate unique roles for each of the dation. The rate-limiting step in mitochondrial oxidation
three PPAR isoforms. The target genes of PPAR par- is entry flux of fatty acids into the mitochondria, which is
ticipate in lipid oxidation [73], suggesting that PPAR is controlled by a carnitine-dependent facilitated transport
mainly involved in lipid catabolism. Conversely, PPAR system. One of its critical components, carnitine palmi-
target genes are generally implicated in the lipogenic toyl transferase I (CPT I), is a direct target gene of PPAR
pathway and the storage of fatty acids in adipose tissue, [87, 88]. In addition, PPAR further regulates the mito-
consistent with a critical role of PPAR in adipogenesis chondrial -oxidiation spiral by modulating the expres-
[20, 74]. Although PPAR/ target genes are poorly sion of the medium-chain acyl CoA dehydrogenase
characterized, the fact that PPAR/ regulates acyl co- (MCAD) gene [89]. The acetyl CoA produced in mito-
enzyme A (CoA) synthase 2 expression suggests a role chondria is converted to ketone bodies, mainly ace-
for this receptor in lipid metabolism [75]. In addition, toacetate and 3-hydroxybutyrate, and serves as an impor-
gene targeting and human genetic studies provide impor- tant energy source for extrahepatic tissues such as brain,
tant clues regarding the functional roles of PPAR recep- renal cortex, heart, and skeletal muscle. The main en-
tors in mammalian metabolism. zyme responsible for generation of ketone bodies is mito-
chondrial hydroxymethylglutaryl-CoA synthase (mHMG-
PPAR in lipid catabolism CoAS), which is directly activated by PPAR [90]. The
PPAR is predominantly expressed in tissues with high critical role of PPAR in fatty acid -oxidation is con-
mitochondrial and peroxisomal -oxidation activities, firmed by the studies in PPAR-null mice [91]. These
exemplified by its high levels in liver, heart and renal animals are unresponsive to PPAR ligand stimulation
cortex and intestine. Its known target genes comprise a in both peroxisomes and mitochondria, and exhibit fatty
relatively homogenous group of genes involved in almost liver. Basal expression of mitochondrial enzymes are
all aspects of lipid metabolism, including uptake, binding lower in PPAR knockout mice versus wild-type mice.
and oxidation of fatty acids, lipoprotein assembly and PPAR also plays an important role in regulating mi-
lipid transport [11]. PPAR activated genes include fatty crosomal -oxidation of fatty acids and eicosanoids. The
acid transport protein (FATP), fatty acid translocase cytochrome P450 4 A (CYP4a) enzymes are central en-
(FAT/CD36) and hepatic cytosolic fatty acid binding zymes participating in this process. For example, -oxi-
protein (L-FABP), and it may play critical roles in uptake dation is the first step in the degradation of leuko-
of fatty acids in the digestive tract [76, 77]. Other genes triene B4 (LTB4), a PPAR ligand [92, 93]. To date, at
involved in the transformation of long-chain fatty acids least two CYP4A enzymes have been shown to be direct
into triglycerides and their incorporation into chylomi- target genes of PPAR: 4A1 in rat and 4A6 in rabbit.
Putative PPRE sites have been reported in the promotercrons and VLDL particles, such as acyl CoA synthase
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region of these genes and PPAR agonists are able to inant PPAR isoform expressed in bone osteoclasts, im-
plicating it in regulating resorption of mineralized boneenhance their expression both in vivo and in vitro [94–97].
Since 4A1 and 4A6 are active arachidonate-hydroxylase surface [106]. Activation of PPAR/ by carbaprosta-
cyclin significantly induced both bone-resorbing activity[98], these data suggest that PPARmay actively partici-
pate in the oxidation of a variety of endogenous lipids and mRNA expression of the osteoclastic genes includ-
ing carbonic anhydrase type II (CA II) and cathepsin K.as well as exogenous compounds in microsomes.
Additional PPAR target genes include apolipopro- Moreover, these effects were completely blocked by an
antisense oligonucleotide of PPAR/, suggesting a criti-tein (apo) I, apo-II and apo C-III. PPAR ligand fibrates
decrease apo C-III by activation of PPAR, leading to cal role for PPAR/ in modulating osteoclastic bone
resorption.enhanced LPL-mediated catobolism of very low-density
lipoprotein (VLDL) particles [99–101]. In contrast, PPAR
PPAR and adipogenesisactivation increases plasma levels of HDL and its major
constituents, apo A-I and A-II through PPAR/RXR het- PPAR has been the most extensively investigated
PPAR isoform. The receptor has been cloned from manyerodimers [79, 102]. These effects, together with negative
regulation of apo C-III, contribute to the hypolipidemic species and identified as the isoform most highly ex-
pressed in adipose tissues. The expression of adipocyteeffects of fibrates. Based on these observations, PPAR
is a critical player in lipid catabolism, including peroxi- fatty acid binding protein (aP2), as well as many other
adipose target genes including lipoprotein lipase (LPL),somal and mitochondrial oxidation, microsomal-oxida-
tion, ketogenesis, and lipid transport. fatty acid translocase (FAT), fatty acid transport protein
(FATP), ACS, malic enzyme (ME), insulin-dependent
PPAR/ in development, fertility, bone formation glucose transporter (GLUT4) and c-Cbl-associated pro-
and lipid metabolism tein (CAP), are activated by PPAR ligands [49, 86].
This array of PPAR target genes is consistent with theWhile it has been widely accepted that PPAR and
PPAR are two key players in lipid metabolism, it now role of PPAR in lipid accumulation. Moreover, a gain-
of-function study showed that forced ectopic expressionappears likely that PPAR/ is also involved in lipid
homeostasis. A recent study by Leibowitz et al showed of PPAR in fibroblasts produced a marked stimulation
adipogenesis in the presence of PPAR activators [107,that PPAR/ specific agonist L-165041 significantly in-
creased high-density lipoprotein (HDL)-cholesterol lev- 108]. This observation was confirmed further in vivo.
Mutation of Pro115Gln in PPAR destroys a MAP ki-els without effects on blood glucose or triglycerides con-
centration in db/db obese mice. These results suggest that nase target site in Ser112, resulting in increased activity
of PPAR receptor and severe obesity in humans [63].PPAR/ agonists could be a novel therapeutic agents in
dyslipidemia [103]. Conversely, in vitro introduction of a dominant negative
PPAR mutant with a defective transactivation domainUbiquitous expression, poor availability of specific li-
gands and lack of a connection to clinical disorders have blocked TZD-induced terminal differentiation of human
pre-adipocytes [109]. Unfortunately, loss-of-function (geneimpeded progress in elucidating the specific function of
PPAR/. PPAR/ expression is particularly high in knockout) studies of adipogenesis using gene targeting
have been hampered by an unexpected requirement ofcertain developing and adult tissues, such as central ner-
vous system, kidney and placenta [34, 35, 66]. This expres- PPAR for placental development and embryonic le-
thality [110]. Recently, several lines of evidence sup-sion pattern indicates a potential function of PPAR/
in these tissues. For example, PPAR/ has been found ported the critical role of PPAR in adipogenesis in vivo.
Study on mice chimeric for wild-type and PPAR-nullto be predominant isotype expressed in the uterus during
the pre-implantation period in mice [104]. Its expression cells showed that PPAR (	/	) embryonic stem (ES)
cells fail to contribute to adipose tissues, whereas mostwas induced in the stroma surrounding the implanting
blastocyst and localized in the decidual zone postimplan- other organs examined did not require PPAR for
proper development [18]. These data support an essen-tation. Its obligate partner RXR was also highly ex-
pressed in endometrial cells and decidua. In addition, tial role for PPAR in fat formation. Similar conclusions
were supported in another study using PPAR mutantPGI2, an endogenous PPAR/ ligand, is generated in
stromal cells at the site of implantation. More impor- mice generated by supplementing PPAR null embryos
with wild-type placenta, via aggregation with tetraploidtantly, the PPAR/ agonists such as carbaprostacyclin
or L-165041 in combination of 9-cis retinoic acid were embryos [110]. The live-born PPAR null mice were
notable for total absence of white and brown adiposeable to restore implantation in the COX-2 gene knockout
mice, in whom defects in implantation and decidualiza- tissue (lipodystrophy). Taken together, these data dem-
onstrate that PPAR is required for adipogenesis both intion were previously reported [104, 105]. These data sug-
gest that PPAR/ plays an essential role in fertility. vitro and in vivo. Thus, together with a number of other
transcription factor including CAAT/enhancer bindingRecently, PPAR/ has been reported to be the predom-
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proteins (C/EBPs), sterol regulatory element binding pro- and mFABP may be responsible, at least in part, for
teins (SREBPs) and PPAR/, PPAR promotes and enhanced insulin sensitivity. TZD PPAR ligands have
maintains adipocyte function [19, 86, 111, 112]. been also shown to ameliorate TNF--induced insulin
resistance, suggesting that suppression of TNF- activa-
tion also might be involved in favorable effect of TZDsPPARS AND RENAL DISEASE
in diabetes and insulin resistance [127, 128].
Beyond a role in adipogenesis, PPARs have been Most recently, a new adipocyte-secreted hormone des-
linked to many human diseases including obesity, insulin ignated resistin (for “resistant to insulin”) has been pro-
resistance, type II diabetes, atherosclerosis, hyperten- posed as a molecular link between obesity and type II
sion, inflammation and cancer. Ligands for these recep- diabetes. TZD rosiglitazone markedly reduced resistin’s
tors have been suggested to have therapeutic potential
expression in adipocytes as well as its circulating level.
for selected human diseases.
Resistin appears to play a role in pathogenesis of insu-
lin resistance [129, 130], since administration of neu-
PPAR, insulin resistance, and type II diabetes tralizing antibody to resistin significantly improved blood
glucose and insulin action in mice with diet-induced obe-Numerous studies have supported a therapeutic role
sity, suggesting that TZD activation of PPAR mightfor PPAR in the treatment of type II diabetes. TZD
increase insulin sensitivity by suppressing the productionPPAR ligands including troglitazone (Rezulin), piogli-
of resistin by adipocytes.tazone (ACTOS) and rosiglatazone (Avandia) are a
Despite the successful use of TZDs as antidiabeticrelatively new class of oral antidiabetic agents that im-
drugs, the specific role of altered PPAR function in theprove all three primary defects in patients with type II
pathogenesis of insulin resistance and type II diabetesdiabetes, that is, insulin resistance, hyperinsulinemia and
remains uncertain. It has long been known that obesityhyperglycemia [113]. Troglitazone significantly reduces
plasma glucose, % glycosylated hemoglobin, insulin and is a major risk factor in the development of type II
C-peptide level in type II diabetes [113–116]. Moreover, diabetes. In obese rats, TZDs increase the number of
this agent also shows beneficial effects of lipid metabo- small adipocytes and decrease the number of large adipo-
lism, blood pressure and cardiac output [113, 117]. These cytes through adipocyte differentiation induced by
effects are generally thought to be mediated by activation PPAR activation [131, 132]. Troglitazone may increase
of PPAR and enhanced insulin sensitivity in peripheral insulin sensitivity through these small adipocytes via in-
tissues [118]. In support of this, ligands of RXR, the hibition of TNF- expression and decreased plasma lip-
obligate partner of PPAR, also exhibit a glucose- and ids [127]. In humans, loss-of-function mutations of
lipid-lowering activity [119] that is additive to a PPAR PPAR share elements of the insulin resistance syn-
agonist [120]. Although TZDs have been successfully drome (insulin resistance, type II diabetes, hypertension
used in the treatment of type II diabetes, the relevant and dyslipidemia), but not obesity [133]. In contrast,
tissue targets remains undefined. Since PPAR is abun- patients with a gain-of-function mutation of PPAR are
dantly expressed in adipose tissues, fat cells have been obese, but have a relatively low level of insulin and
implicated as a primary target tissue for TZDs [121]. increased sensitivity to insulin [63]. These data suggest
Arguing against this hypothesis is the observation that that excess PPAR activity contributes to obesity and
mice genetically manipulated to delete adipose tissue
reduced PPAR activity elicits insulin resistance. How-
develop severe insulin resistance, and that troglitazone
ever, studies on mice heterozygous for the PPAR geneameliorates hyperinsulinemia and hyperglycemia in this
paint a more complex picture [134, 135]. PPAR (/	)model as well [122]. This suggests that the insulin-sensi-
mice develop normally, have a normal number and sizetizing effects of TZD are independent of effects on adi-
of adipocytes and show no metabolic defect. However,pose tissues. Another proposed target tissue for TZDs
the size of the adipocytes in PPAR (/	) mice on ais skeletal muscle, the major site of impaired insulin
high-fat diet is much smaller than those in wild-type mice,action in type II diabetes. PPAR has been found to be
and PPAR (/	) mice unexpectedly exhibit enhancedexpressed in skeletal muscle tissue [123] and its expres-
insulin sensitivity and reduced weight gain as comparedsion is enhanced in type II diabetic patients [60, 124–126].
to wild-type mice. In this setting, PPAR may promoteThe activation of PPAR increases expression of adipo-
small adipocyte formation, which is insulin sensitive. Oncyte lipid binding protein (ALBP) and muscle fatty acid
the other hand, PPAR activation can stimulate hyper-binding protein (mFABP) in this tissue [125], potentially
trophy (large adipocytes) of pre-existing adipocytes,modulating lipid and fatty acid uptake. Fatty acids are
which leads to insulin resistance. Taken together, thesekey regulators of insulin sensitivity. It is well-established
data suggest a complex role for PPAR in adiposity andthat fatty acids decrease glucose usage in skeletal muscle.
PPAR-induced increase in fatty acids uptake by ALBP insulin resistance.
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PPARs and obesity genes implicated in energy homeostasis, including TNF-
and UCPs [127, 155]. These data suggest that multipleBoth PPAR and PPAR receptors have been impli-
mechanisms contribute to the pathogenic role of PPARcated in the pathogenesis of obesity. PPAR agonist
in obesity.fibrate treatment has been reported to reduce weight
gain in rodents [136, 137]. Moreover, PPAR null mice PPAR and hypertension
accumulate more body fat with aging [138, 139]. These
Hypertension in Western countries is commonlydata suggest that PPAR plays an important role in
linked to obesity and insulin resistance [156, 157]. Re-obesity. The mechanisms may involve both regulation
cently thiazolidinediones (TZDs) have been found notof lipid catabolism and energy expenditure. PPAR has
only to sensitize tissue to insulin but also to lower bloodbeen shown to increase the expression of uncoupling
pressure in both animals and humans [158–161]. Studiesproteins (UCP-1, UCP-2, and UCP-3), mitochondrial
on hyperinsulinemic Watanabe heritable hyperlipidemicinner-membrane transporters responsible for heat gener-
(WHHL) rabbits or obese Zucker rats show that theation through uncoupling proton entry from ATP syn-
PPAR ligand troglitazone increases insulin sensitivitythesis [140, 141]. UCPs are important regulators of ther-
and lowers blood pressure [159–161]. Similarly, troglita-mogenesis and body weight regulation. All three UCPs
zone has been shown to be effective in amelioratingare abundantly expressed in brown adipose tissue
hypertension in patients with type II diabetes [158]. It(BAT), however, each UCP differs in its expression pat-
has been suggested that the antihypertensive effect oftern in other tissues [142–147]. UCP-1 is relatively re-
TZDs is a result of improved insulin resistance, sincestricted to brown fat tissue [148]. In contrast, UCP-2 is
enhanced insulin sensitivity has been found to be associ-expressed in most tissues at varying levels, while UCP-3
ated with lower blood pressure both in diabetic animalsis expressed predominantly in skeletal muscle and brown
[162–165] and humans [166]. Direct vascular effects ofadipose tissue. Given the wide tissue distribution pattern
PPAR also may play a role, since recent studies haveof UCP-2 and UCP-3, it was originally thought that they
identified PPAR in both endothelium and vascular
may contribute more to adaptive thermogenesis than
smooth muscle cells [167–171]. Studies on one-kidney,
UCP-1. However, increased rather than decreased ex- one-clip hypertensive rats, a model not associated with
pression of UCP-2 and UCP-3 has been observed after insulin resistance, shows that pioglitazone significantly
starvation, a state known to be associated with decreased lowers the blood pressure [172]. It is conceivable that
energy expenditure [149, 150]. Furthermore, although vascular expression of PPAR could modulate the re-
transgenic mice with toxigen-mediated reduction of lease of vasodilator autacoids [173]. Troglitazone has
brown fat (UCP-DTA) develop obesity [151], UCP-1 been reported to dilate peripheral blood vessels both in
targeted mice have a defect in adaptive thermogenesis vitro and in vivo in animals [173, 174] and humans [117,
but not obesity [142]. Thus, based on these undefined 175]. These effects seem to depend on prostaglandin
roles of UCPs in obesity, regulation of PPAR in this synthesis since troglitazone-induced vasorelaxation was
setting of disease requires more investigation. abolished by the prostaglandin synthase inhibitor indo-
The role of PPAR in pathogenesis of obesity appears methacin [175], suggesting that these vasorelaxant effects
more clear. As discussed above, PPAR plays a critical are mediated by locally generated prostanoids, possibly
role in adipogenesis both in vitro and in vivo. Dysfunc- endothelial derived prostacyclin [173]. Other studies sug-
tion of the PPAR receptor has significant effects on gest that antihypertensive effects of TZDs also involve
body fat mass. This has been confirmed both by trans- decreased fatty acid levels, blockade of L-type calcium
genic studies and human genetic studies [152]. Patients channels and modulation of vascular production of vaso-
with an activating missense mutation of the PPAR2 active peptides including type-C natriuretic peptide, en-
protein exhibit accelerated adipocyte differentiation and dothelin, and plasminogen activator inhibitor-1 (PAI-1)
develop severe obesity [63]. In contrast, patients with a [176, 177]. Alternatively, PPARmay directly affect vas-
PPAR2 mutation associated with decreased receptor cular smooth muscle cell (VSMC) tone. Troglitazone has
activity exhibit lower body mass and improved insulin been shown to inhibit VSMC proliferation and migration
sensitivity [64]. Together with the previously discussed in vitro [40, 168], as well as following angioplasty [178].
effects of PPAR disruption on adiposity in knockout Finally, PPAR has been identified in collecting ducts
mice, these data clearly demonstrate that PPAR plays and glomeruli (abstract; Guan et al, J Am Soc Nephrol
a critical role in obesity. These effects on adipocytes may 11:A3381, 2000) [35]. Constitutive expression of PPAR
include modulation of leptin-stimulated lipolysis and glu- in these segments might have important regulatory ef-
cose utilization. Thiazolidinediones inhibit leptin pro- fects on salt and water absorption. These effects could
duction [153] through PPAR-dependent PPRE in pro- contribute to the edema complicating treatment using
moter region of the leptin (ob) gene [154]. In addition, TZDs in patients and animals [161, 179, 180]. Taken
together, these data suggest that PPAR expression con-PPAR has been also shown to regulate many other
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tributes to blood pressure regulation through multiple ular mesangial cells (abstract; Guan et al, J Am Soc
Nephrol 11:A3381, 2000). It is well established that mes-mechanisms.
angial cells play an important role in the progression of
PPARs and kidney disease nephropathy. During inflammatory injury or high glu-
cose stimulation, mesangial cells undergo a process ofThe role of PPAR isoform expression in the kidney is
just now being elucidated, All three PPAR isoforms are activation from a quiescent phenotype to a proliferative
myofibroblast-like phenotype, characterized by increasedexpressed in the kidney of many species including hu-
mans [35, 69, 72]. PPAR expression predominates in -smooth muscle actin and pro-inflammatory cytokines,
as well as enhanced production of extracellular matrixthe proximal tubule and thick limb, and could contribute
to dietary lipid-induced gene expression of peroxisomal proteins [186–188]. This phenotypic alteration has been
considered a fundamental feature in the development ofand mitochondrial -oxidation in these segments [181].
The PPAR agonist clofibrate significantly induced ex- diabetic nephropathy and glomerulonephritis. Studies
by Asano et al showed that the TZD PPAR ligands,pression of -oxidation enzymes in renal cortex, includ-
ing long-chain acyl CoA dehydrogenase (LCAD), me- troglitazone, and endogenous PPAR ligand, 15dPGJ2,
can significantly suppress the production of -smoothdium-chain acyl CoA dehydrogenase (MCAD) and acyl
CoA oxidase (ACO). These data suggest that renal muscle actin, indicating that PPAR activation may in-
hibit de-differentiation of mesangial cells [70]. In addi-PPAR plays a major role in triggering fatty acid utiliza-
tion and the adaptive response to dietary lipids in the tion, in vitro studies have shown PPAR ligands can
significantly inhibit proliferation of mesangial cells in akidney. Notably, renal PPAR also colocalizes with P450
4 A enzymes, which are known PPAR target genes [93] dose-dependent manner [70]. These data suggest that
PPAR activation may reverse the phenotypic changethat appear to be involved in blood pressure regulation
[182]. Interestingly, clofibrate has been shown to reduce of mesangial cells and induce cell growth arrest and re-
duction of extracellular matrix production. Therefore,blood pressure in Dahl salt-sensitive rats [183]. These
findings suggest that PPAR participates in blood pres- glomerular PPAR activation could be a therapeutic
target for treating diabetic nephropathy. Indeed, trogli-sure regulation through activation of P450 4 A enzymes
in the proximal tubules. In addition, PPAR has also tazone treatment has been shown to ameliorate micro-
albuminuria both in the streptozotocin-induced diabeticbeen shown to play an important role in maintaining a
sustained balance of energy production/utilization in the rat and type II diabetic patients [189, 190]. In the fa/fa
rat, a genetic model of type II diabetes, intervention withkidney through regulating expression of genes involved
in fatty acid -oxidation [184]. This effect may contribute troglitazone decreased proteinuria and halted the early
onset and progression of mesangial expansion and glo-to the observation that PPAR ligands appear to protect
kidney from ischemia/reperfusion injury in rats [184]. Mice merulosclerosis [191]. Similarly, pioglitazone and rosigli-
tazone markedly reduce proteinuria and slow the pro-lacking the PPAR gene exhibit more severe cortical ne-
crosis and worse kidney function than wild-type control gression of diabetic nephropathy in genetically obese
diabetic rats [161, 192].animals [184]. These findings help to explain the molecular
mechanisms by which ischemia/reperfusion leads to sup- Accumulating evidence suggests that TZDs have di-
rect and beneficial glomerular effects. A recent study inpression of fatty acid -oxidation, and might provide a
new therapeutic strategy for ischemic renal injury. streptozotocin-induced diabetic rat showed that troglita-
zone was not only able to prevent diabetic glomerularPPAR mRNA is also highly expressed in the kidney,
but in contrast to PPAR is predominantly expressed hyperfiltration and albuminuria, but also to reduce mRNA
expression of extracellular matrix proteins (fibronectinin collecting ducts, which suggests that this isoform might
play a role in systemic water and sodium retention. In and type IV collagen) and TGF-1 in diabetic glomeruli.
These beneficial effects in insulin-dependent diabetesfact, in both rodents and humans, treatment with TZD
PPAR ligands may cause marked fluid retention, edema mellitus suggest that PPAR ligands can protect glomer-
ular function independently of their capacity to increaseand hemodilution [161, 179, 180]. Although other mecha-
nisms may be involved, the possibility that collecting duct glucose tolerance. Furthermore, in a nondiabetic glomer-
ulosclerotic model, PPAR ligands were effective in pre-PPAR activation is responsible for water and sodium
retention in TZD-treated diabetic patients has not been venting the deterioration of renal function. In a 5/6 abla-
tion model of renal failure, Ma et al recently noted thatexamined.
Cultured mesangial cells have also been found to ex- troglitazone treatment significantly reduced proteinuria,
serum creatinine level and glomerulosclerosis possiblypress PPAR [70]. Interestingly they also may produce
a precursor of 15dPGJ2, a putative endogenous PPAR via inhibition of glomerular cell proliferation and reduc-
tion of TGF-1 expression in glomeruli and renal tubules,ligand [185]. A preliminary report also demonstrates the
presence of PPAR in freshly isolated glomeruli, and suggesting a paracrine PPAR system in glomerular mes-
angial cells (Note added in proof). This is consistent withsuggest that a paracrine PPAR system exists in glomer-
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other studies showing a beneficial effect of troglitazone the IL-1–stimulated release of IL-6 and prostaglandin
and expression of cyclooxygenase-2 (COX-2) [199]. Dataon glomeruli. Taken together, these studies suggest that
TZDs may be used as possible therapeutic agents for suggest that these effects were mediated by inhibition
of nuclear factor-B (NF-B) and activator protein-1diabetic nephropathy and glomerulosclerosis.
Finally, both PPAR and PPAR have potent anti- (AP-1), two ubiquitous transcription factors that trans-
duce the effects of many pro-atherogenic and inflamma-inflammatory effects in macrophages [42, 193]. It is rea-
sonable to anticipate that PPAR activation might also tory factors [201–203]. PPAR has also been shown to
lower the plasma concentration of fibrinogen, an impor-play a role in renal inflammation, including glomerulone-
phritis and interstitial nephritis; however, thus far few tant risk factor for cardiovascular disease, both in rat
and in human [199, 204]. In addition, PPAR ligandsreports have addressed this important issue. A recent
preliminary report suggested that the PPAR ligand, effectively increased HDL cholesterol level and decreased
the low-density lipoprotein (LDL) cholesterol level introglitazone, significantly enhanced rather than repressed
glomerular expression of MCP-1, a critical cytokine in hyperlipidemic patients, as a result of transcriptional in-
duction of HDL apolipoproteins, apo A-I and apo A-II,recruiting monocytes in glomeruli, in a rat model of mes-
angioproliferative glomerulonephritis (abstract; Panzer and LPL, and inhibition of hepatic apo C-III production
through the PPAR receptor (see above) [4].et al., J Am Soc Nephrol 11:A2625, 2000). These results
raise the possibility that certain PPAR ligands might Little is known about the role of PPAR/ in athero-
sclerosis. Recent evidence has emerged that PPAR/promote, rather than inhibit, the progression of glomeru-
lonephritis. If so, PPAR antagonists could provide a novel might be a target for treatment of dyslipidemia since
a PPAR/ ligand increases the HDL-cholesterol leveltherapeutic approach to renal inflammatory diseases.
[103]. Since hyperlipidemia is a key atherogenic factor,
PPARs, inflammation and atheroscerosis the effect of PPAR/ in increasing HDL-cholesterol
may be beneficial in prevention of atherosclerosis.Renovascular stenosis and atheroemboli represent in-
creasingly common disorders contributing to renal dys- PPAR has also been implicated in at least three
pathologic processes in atherosclerosis: foam cell differ-function in elderly diabetic patients [194, 195]. PPAR
activation also may modify the course of atherosclerosis entiation, inflammatory reaction and cell proliferation.
The infiltrating monocytes in the intima of the arterialvia effects on inflammation, modulation of lipid accumu-
lation in the arterial wall and altered endothelial func- wall take up oxidized LDL via scavenger receptors
(SRAI/II, SR-BI, CD36, etc.), promoting accumulationtion, proliferation of vascular smooth muscle, and foam
cell formation. All three PPAR isoforms may modify of intracellular lipids and generation of lipid-laden foam
cells [205]. It has been shown that the oxidized LDLthe progression of atherosclerosis through multiple
mechanisms including modulation of plasma lipoprotein (OxLDL) scavenger receptor CD36 (fat) is under direct
control of PPAR. PPAR ligand, in combination ofconcentration, foam cell formation, inflammatory re-
sponse and pro-atherosclerotic protein level. RXR agonist LG268, significantly up-regulates the ex-
pression of CD36 and the binding of OxLDL in a mono-Hypolipidemic fibrates (clofibrate and benzofibrate)
are potent PPAR agonists proven to be beneficial in cytic cell line [30]. Interestingly, OxLDL contains natu-
rally occurring PPAR ligands (9-HODE and 13-HODE).the prevention of atherosclerosis [196]. Formation of
atherosclerotic lesions require recruitment of monocytes Furthermore, in the presence of OxLDL, PPAR ex-
pression was markedly induced [206]. This positive feed-into the arterial wall through expression of specific adhe-
sion molecules by endothelial cells. Not only is PPAR back loop could promote atherosclerosis by stimulating
the uptake of OxLDL in macrophage/foam cells. Cyto-expressed in human endothelial cells [197], but its activa-
tion decreases the expression of the adhesion molecule kines produced by these activated macrophage/foam
cells include M-CSF, IL-1, and TNF-, and they initiateVCAM-1 in these cells [198]. Moreover, PPAR has
been implicated in inflammatory processes of the athero- inflammation and induce proliferation of VSMCs. In
contrast, other effects of PPAR might be beneficial insclerotic lesion, which is believed to be responsible for
disruption of atherosclerotic plaque [199]. PPAR-defi- the treatment of atherosclerosis. An anti-inflammatory
effect of PPAR in monocytes has been described.cient mice show a prolonged response to inflammatory
stimuli, suggesting PPAR modulates inflammation PPAR has been shown to reduce cytokine (TNF, IL-1,
and IL-6) production [42], probably by inhibiting the[200]. In hyperlipidemic patients, the PPAR ligand fen-
ofibrate, significantly decreased plasma concentrations activity of pro-inflammatory transcription factors such
as NF-B, AP-1 and STAT [207]. Other favorable effectsof interleukin-6 (IL-6). Anti-inflammatory effects were
also observed in cultured vascular smooth muscle cells of PPAR include induction of apoptosis in monocytes
[208], inhibition of proliferation of VSMCs [37, 178],(VSMCs), which participate in plaque formation and
postangioplasty re-stenosis. PPAR is functionally ac- suppression of metalloproteinase-9 expression [39], and
reduction of plasma triglycerides [209]. On the basis oftive in VSMCs and another ligand, Wy14643, inhibited
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these data, an important role for PPAR in atherosclero- Treatment of cultured breast cancer cells with troglita-
zone results in cell growth arrest and promotes differenti-sis remains uncertain.
Most recently, two studies provide clear evidence that ation [44]. Troglitazone has also been shown to inhibit
tumor growth and induce apoptosis in human breastTZDs treatment reduced atherosclerosis in vivo [210,
211]. In the Watanabe heritable hyperlipidemic (WHHL) cancer cells in vitro and in BNX mice [218]. Moreover,
another PPAR ligand, GW7845, has been shown torabbits, troglitazone treatment potently reduced the de-
velopment of atherosclerotic lesions [210]. Similarly, ro- decrease tumor incidence, tumor growth and tumor bur-
den in the NMU induced mammary carcinoma [219].siglitazone improved atherosclerotic lesions in LDL re-
ceptor knockout mice [211]. These data suggest that the These data suggest that PPAR ligands may be used as
novel, nontoxic and selective chemotherapeutic agentsanti-atherogenic effect of TZDs outweighs its pro-ath-
erogenic effects in vivo. Although it is uncertain whether for human breast cancer. A role for PPAR activation
also has been suggested in human transitional bladderthe reduction in atherosclerosis following TZD treat-
ment is a direct effect of PPAR activation in macro- cancers [46]. PPAR is highly expressed in normal as
well as malignant human transitional cell bladder cancer.phages or an indirect effect secondary to improvements
of insulin sensitivity, several lines of evidence demon- Several PPAR ligands (including troglitazone, ciglita-
zone and 15dPGJ2) significantly inhibit growth in cul-strated that PPAR is not required for differentiation
of macrophage lineage and the formation of foam cells tured human bladder cancer cells, and this action is asso-
ciated with induction of cyclin-dependent kinase inhibitors[212, 213]. More importantly, PPAR activation can pro-
mote cholesterol removal from human foam cells (p21 and p16) and reduction of cyclin D expression. Im-
portantly, RXR ligands 9-cis retinoic acid and LG100268through stimulation of ABCA1, a protein involved in
cholesterol export [212]. Additionally, PPAR activation exhibited synergy with PPAR ligands in inducing cell
death. Anti-tumor effects of PPAR ligands have beenalso results in the down-regulation of the LDL receptor
scavenger SR-A in mouse macrophage [213]. Thus, mac- observed in human prostate cancer and gastric cancer
as well [43, 220]. Conversely, the role of PPAR in hu-rophage is a direct target for TZD and PPAR activation
has multiple effects on the influx and efflux of cholesterol man colon cancer remains controversial. While PPAR
is expressed in human colon tumor and in cultured colonand oxidized lipid, countering their atherosclerotic ef-
fects of CD36 induction [214]. Data from a clinical trial of cell lines [221, 222], two groups recently reported that
PPAR ligands promote polyp formation in APCmin/PPAR ligands in dyslipidemic patients without type II
diabetic patients will be required to clarify the role of mice, a murine model of the human genetic disease famil-
ial adenomatous polyposis coli (FAP) [223, 224]. ThesePPAR in this setting of disease.
studies showed that when such mice are treated with
PPARs, the cell cycle and cancer troglitazone or with rosiglitazone, they develop an in-
creased frequency of large but not small bowel polyps.Effects of PPARs on renal cell proliferation seem likely,
but remain unexplored. All three isoforms of PPAR have In contrast, troglitazone reduces colon tumor xenograft
volume in nude mice [222]. This corresponds to in vitrobeen suggested to play a role in regulating the cell cycle
and in carcinogenesis. PPAR, the predominant form studies showing that activation of PPAR results in colon
cancer cell cycle arrest (G1 phase) and differentiationof PPAR in the liver, is involved in the growth promoting
and hepatocarcinogenic effect of peroxisome prolifera- [221], supporting the idea that PPAR activation might
be beneficial for human colon cancer as well. The differ-tors in rodents [15]. However, these rodent data do not
appear relevant to humans. No carcinogenic effect of ent effects of troglitazone on polyp formation and cancer
growth may reflect important biological differences inperoxisome proliferators has been shown in humans,
possibly because of the much lower level of PPAR the two processes.
Recently, an important role for PPAR/ in carcino-expression in human hepatocytes as a result of exon 6
splicing of PPAR transcripts [53]. genesis has been proposed [65]. PPAR/ expression
appears to be increased in colorectal cancer and localizedPotent effects of PPAR on cell proliferation and cell
cycling have been described. PPAR ligands can trigger in dysplastic epithelial cells [225]. The NSAID sulindac,
which suppress colorectal tumorigenesis, can antagonizecell cycle arrest in NIH3T3 cells and HIB-1B cells [215].
PPAR ligands can also induce terminal differentiation PPAR/-activated gene transcription in an in vitro
assay system. These findings suggest that NSAIDs mayand withdrawal of human liposarcoma cells from the cell
cycle [216]. Importantly, TZD PPAR ligands have been inhibit tumorigenesis through inhibition of PPAR/ ac-
tivity, thereby contributing to their chemopreventive ef-found to slow the progression of advanced liposarcoma
in humans [217]. Given the expression of PPAR in non- fects [226], and raise the possibility that PPAR/ antag-
onists might have chemopreventive effects in humanadipose tissues, the effect of PPAR on human breast
cancer, gastric cancer, prostate cancer, colon cancer and colorectal cancer. Specific roles of PPARs in renal can-
cers and cystic disease remain unexplored.transitional cell bladder cancer have been explored.
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